Market capitalization | $13.21m |
Enterprise Value | $-14.10m |
P/E (TTM) P/E ratio | 2.55 |
EV/FCF (TTM) EV/FCF | 4.91 |
P/B ratio (TTM) P/B ratio | 0.28 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-5.71m |
Free Cash Flow (TTM) Free Cash Flow | $-2.87m |
Cash position | $32.64m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
Jul '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -5.71 -5.71 |
17%
17%
|
EBIT (Operating Income) EBIT | -5.71 -5.71 |
17%
17%
|
Net Profit | 27 27 |
553%
553%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.
Head office | United States |
CEO | Joshua Silverman |
Employees | 2 |
Founded | 1996 |
Website | pharmacyte.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.